8-K

a5521350.txt

PFIZER INC., 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): October 15, 2007

PFIZER INC.

(Exact name of registrant as specified in its charter)

Delaware 1-3619 13-5315170

(State or other (Commission File (I.R.S. Employer

jurisdiction of (Number) Identification No.)

incorporation)

235 East 42nd Street 10017

New York, New York (Zip Code)

(Address of principal executive offices)

Registrant's telephone number, including area code:

(212) 573-2323

Not Applicable

(Former Name or Former Address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to

simultaneously satisfy the obligation of the registrant under any of the

following provisions (see General Instruction A.2. below):

[] Written communication pursuant to Rule 425 under the Securities Act (17 CFR

230.425)

[] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR

240.14a-12)

[] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange

Act (17 CFR 240.14d-2 (b))

[] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange

Act (17 CFR 240.13e-4(c))

Item 2.02 Results of Operations and Financial Condition

On October 18, 2007, Pfizer Inc. ("Pfizer") issued a press release and related

materials (collectively, the "October 18, 2007 Press Release") announcing its

financial results for the third quarter of 2007, including charges relating to

its decision to exit Exubera, an inhaled insulin product. The October 18, 2007

Press Release is deemed to be "filed" under the Securities Exchange Act of 1934

as Exhibit 99 to this report and is incorporated herein by reference.

Item 2.05 Costs Associated with Exit or Disposal Activities

On October 15, 2007, the Company made a decision to exit Exubera, an inhaled

insulin product. This decision resulted in total pre-tax charges of $2.8 billion

(including exit costs)in the third quarter of 2007. Additional information

concerning this decision and the related charges is provided in the October 18,

2007 Press Release, which is deemed to be "filed" under the Securities Exchange

Act of 1934 as Exhibit 99 to this report is incorporated by reference herein.

Item 2.06 Material Impairments

On October 15, 2007, the Company made a decision to exit Exubera, an inhaled

insulin product. This decision resulted in total pre-tax charges of $2.8 billion

(including asset impairments) in the third quarter of 2007. Additional

information concerning this decision and the related charges is provided in the

October 18, 2007 Press Release, which is deemed to be "filed" under the

Securities Exchange Act of 1934 as Exhibit 99 to this report is incorporated by

reference herein.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit 99 Press Release of Pfizer Inc. dated October 18, 2007, reporting

Pfizer's financial results for the third quarter of 2007,

including charges relating to its decision to exit Exubera, an

inhaled insulin product. Exhibit 99 is deemed to be "filed" under

the Securities Exchange Act of 1934 in this Current Report on

Form 8-K.

SIGNATURE

Under the requirements of the Securities Exchange Act of 1934, the registrant

has caused this report to be signed on its behalf by the authorized undersigned.

PFIZER INC.

By: /s/ Margaret M. Foran

----------------------------

Margaret M. Foran

Title: Senior Vice President-Corporate Governance,

Associate General Counsel and Corporate Secretary

Dated: October 18, 2007

EXHIBIT INDEX

Exhibit No. Description

99 Press Release of Pfizer Inc. dated October 18, 2007, reporting

Pfizer's financial results for the third quarter of 2007,

including a charge relating to its decision to exit Exubera, an

inhaled insulin product. Exhibit 99 is deemed to be "filed" under

the Securities Exchange Act of 1934 in this Current Report on

Form 8-K.